SARM1 activation triggers axon degeneration locally via NAD⁺ destruction - PubMed
- ️Thu Jan 01 2015
SARM1 activation triggers axon degeneration locally via NAD⁺ destruction
Josiah Gerdts et al. Science. 2015.
Abstract
Axon degeneration is an intrinsic self-destruction program that underlies axon loss during injury and disease. Sterile alpha and TIR motif-containing 1 (SARM1) protein is an essential mediator of axon degeneration. We report that SARM1 initiates a local destruction program involving rapid breakdown of nicotinamide adenine dinucleotide (NAD(+)) after injury. We used an engineered protease-sensitized SARM1 to demonstrate that SARM1 activity is required after axon injury to induce axon degeneration. Dimerization of the Toll-interleukin receptor (TIR) domain of SARM1 alone was sufficient to induce locally mediated axon degeneration. Formation of the SARM1 TIR dimer triggered rapid breakdown of NAD(+), whereas SARM1-induced axon destruction could be counteracted by increased NAD(+) synthesis. SARM1-induced depletion of NAD(+) may explain the potent axon protection in Wallerian degeneration slow (Wld(s)) mutant mice.
Copyright © 2015, American Association for the Advancement of Science.
Figures

SARM1 functions following axon injury to promote destruction. A) Schematic showing how expression of SARMps-Frb-Ntev with Fkbp-Ctev allows rapamycin-induced complementation of split TEV and concomitant SARMps cleavage. B) Gel electrophoresis with anti-GFP immunoblot showing SARMps cleavage in DRG neurons induced by 100 nM rapamycin (rapa); FL=full length SARMps-Frb-Ntev-Cerulean; clv = cleaved form. α-Tubulin (αTub) was a loading control. C) Diagram of in vitro injury model: isolated DRG neurons were severed and axon degeneration was quantified after 24 hours from axon images. D) Requirement for SARM1 activity after axotomy to induce axon degeneration.. Axon degeneration is reported as the degeneration index (DI), a morphometric ratio of fragmented axon area to total axon area (13). Sarm1−/− DRG neurons treated with expression lentiviruses (control, SARMps-FrbNtev, and Fkbp-Ctev) were severed and treated with 100 nM rapamycin at various times (pre = 12 hours pre-injury). E) Micrographs show representative α-Tubulin stained axons corresponding to select treatment groups in (D). Scale bar = 50 micrometers. Error bars = SEM; * p < 0.01; one-way analysis of variance (ANOVA) with Tukey’s post-hoc test.

Axon degeneration and neuronal death induced by sTIR dimerization. A) Micrograph showing motor nerves of third instar Drosophila larvae. M12-Gal4 drives expression from mCD8-GFP (green) alone or with either UAS-SAM-TIR or UAS-SAM-TIRmut in single motor axons in each nerve (red=HRP). UAS-SAM-TIR expression caused axon loss in 49/49 nerves as shown; whereas SAM-TIR with a disruptive TIR mutation led to degeneration in 0/70 nerves (χ2=119; p<0.001); scale bar=10 micrometers. B) Schematic showing sTIR dimerization by rapamycin or AP20187. C) Effect of sTIR, dimerized sTIR, and rapamycin on axon degeneration. α-Tubulin stained axons correspond to bars b and d. D) Effect of sTIR dimerization on neuronal viability quantified by ethidium homodimer exclusion after 24 hours. E) Effects of dimerization of sTIR or TIR domains of MYD88 or TLR4 on axon degeneration. F) Effects of sTIR dimerization on degeneration of Sarm1−/− axons physically disconnected from cell bodies. G) Left: diagram of axons growing through a diffusion barrier into an isolated fluid compartment. Right: micrographs of isolated distal axon segments after application of AP20187 globally or selectively to distal axons. Scale bar = 50 micrometers. Error bars = SEM; * p < 0.01; one-way ANOVA with Tukey’s post-hoc test.

Loss of NAD+ underlies SARM1-induced destruction. A) Diagram of NAD+ synthesis and inhibition by FK866; Nam=nicotinamide, NR = nicotinamide riboside, Nrk=nicotinamide riboside kinase, NMN=nicotinamide mononucleotide. B) Axonal NAD+ concentration in cultured wild-type and Sarm1−/− DRG neurons following axotomy; normalized to wild-type control. C) NAD+ concentration in distal sciatic nerve segments from wild-type or Sarm1−/− animals following transection; wild-type n=5; Sarm1−/− n=9. D) Neuronal NAD+ and ATP concentrations following sTIR dimerization by AP20187; comparisons made to zero minutes control. E–F) Axon degeneration (E) and neuronal cell death (F) induced by sTIR homodimerization (AP20187) and inhibition by NAD+ synthetic enzymes with or without the Nampt inhibitor FK866 (10 nM); measured 24 hours after sTIR dimerization and FK866 application. G–H) Effect of NR (1 mM) on axon degeneration (G) and neuronal cell death (H) induced by sTIR homodimerization (AP20187) for 24 hours with or without NR. I) Micrographs showing sTIR-induced motor axon fragmentation in third instar Drosophila larvae blocked by cytosolic Nmnat1 (cytNmnat1) expression. M12-Gal4 drives expression from UAS-mCD8-GFP (green) and UAS-FkF36VTIR with or without UAS-cytNmnat1 in single motor axons in each nerve (red=HRP). Degeneration score = 76+/−4% (control) vs 11+/−2% (cytNmnat1); p<0.001 (t-test); scale bar=20 micrometers. Error bars = SEM; * p < 0.01; one-way ANOVA with Tukey’s post-hoc test.

Effects of NAD+ breakdown on axon degeneration. A) Diagram of NAD+ manipulation using Tnkp dimerization. NAD+ loss induced by FkbpF36V-Tnkp dimerization is blocked by Tankyrase inhibitor XAV939 or NR and is exacerbated by FK866. B) Axon degeneration in response to NAD+ depletion by dimerized Tnkp and FK866 after 24 hours (bar d) and inhibition by Tankyrase inhibitor XAV939 (100 nM; bar e). Representative α-Tubulin-stained axons corresponding to bars b and d are shown; scale bar = 50 micrometers. C) Effect of NAD+ depletion by dimerized Tnkp + FK866 on axon degeneration in Sarm1−/− uninjured axons (bar b) or isolated (cut) Sarm1−/− axons (bar d). D) Effect of sTIR dimerization on endogenous (dotted lines) and exogenously introduced (solid lines) NAD+ or NaAD (control) in HTir cells. NaAD is undetectable in non-electroporated cells. E) Conversion of 14C-NAD+ in HTir cells to Nam 15 minutes after SARM1 TIR dimerization. NAD+ and Nam from cell extracts and extracellular media were resolved by thin layer chromatography. F) Top: effect of the PARP inhibitor olaparib (100 nM) on NAD+ loss induced by 1 mM H2O2 (10 min) or sTIR dimerization (10 min). Bottom: PAR formation after H2O2 treatment or sTIR dimerization in HTir cells expressing PARG shRNA and inhibition by olaparib. Error bars = SEM; * p < 0.01; one way ANOVA with Tukey’s post-hoc test.
Similar articles
-
Summers DW, Gibson DA, DiAntonio A, Milbrandt J. Summers DW, et al. Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6271-E6280. doi: 10.1073/pnas.1601506113. Epub 2016 Sep 26. Proc Natl Acad Sci U S A. 2016. PMID: 27671644 Free PMC article.
-
SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration.
Figley MD, Gu W, Nanson JD, Shi Y, Sasaki Y, Cunnea K, Malde AK, Jia X, Luo Z, Saikot FK, Mosaiab T, Masic V, Holt S, Hartley-Tassell L, McGuinness HY, Manik MK, Bosanac T, Landsberg MJ, Kerry PS, Mobli M, Hughes RO, Milbrandt J, Kobe B, DiAntonio A, Ve T. Figley MD, et al. Neuron. 2021 Apr 7;109(7):1118-1136.e11. doi: 10.1016/j.neuron.2021.02.009. Epub 2021 Mar 2. Neuron. 2021. PMID: 33657413 Free PMC article.
-
Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism.
Gerdts J, Summers DW, Milbrandt J, DiAntonio A. Gerdts J, et al. Neuron. 2016 Feb 3;89(3):449-60. doi: 10.1016/j.neuron.2015.12.023. Neuron. 2016. PMID: 26844829 Free PMC article. Review.
-
The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products.
Garb J, Amitai G, Lu A, Ofir G, Brandis A, Mehlman T, Kranzusch PJ, Sorek R. Garb J, et al. PLoS One. 2024 Apr 18;19(4):e0302251. doi: 10.1371/journal.pone.0302251. eCollection 2024. PLoS One. 2024. PMID: 38635746 Free PMC article.
-
The chemical biology of NAD+ regulation in axon degeneration.
Icso JD, Thompson PR. Icso JD, et al. Curr Opin Chem Biol. 2022 Aug;69:102176. doi: 10.1016/j.cbpa.2022.102176. Epub 2022 Jul 1. Curr Opin Chem Biol. 2022. PMID: 35780654 Free PMC article. Review.
Cited by
-
TMEM184b Promotes Axon Degeneration and Neuromuscular Junction Maintenance.
Bhattacharya MR, Geisler S, Pittman SK, Doan RA, Weihl CC, Milbrandt J, DiAntonio A. Bhattacharya MR, et al. J Neurosci. 2016 Apr 27;36(17):4681-9. doi: 10.1523/JNEUROSCI.2893-15.2016. J Neurosci. 2016. PMID: 27122027 Free PMC article.
-
NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD+ depletion.
Sasaki Y, Nakagawa T, Mao X, DiAntonio A, Milbrandt J. Sasaki Y, et al. Elife. 2016 Oct 13;5:e19749. doi: 10.7554/eLife.19749. Elife. 2016. PMID: 27735788 Free PMC article.
-
Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process.
Khaidizar FD, Bessho Y, Nakahata Y. Khaidizar FD, et al. Int J Mol Sci. 2021 Apr 2;22(7):3709. doi: 10.3390/ijms22073709. Int J Mol Sci. 2021. PMID: 33918226 Free PMC article. Review.
-
Mechanisms of the NAD+ salvage pathway in enhancing skeletal muscle function.
Su M, Qiu F, Li Y, Che T, Li N, Zhang S. Su M, et al. Front Cell Dev Biol. 2024 Sep 20;12:1464815. doi: 10.3389/fcell.2024.1464815. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39372950 Free PMC article. Review.
-
Sun Y, Wang Q, Wang Y, Ren W, Cao Y, Li J, Zhou X, Fu W, Yang J. Sun Y, et al. Protein Cell. 2021 Aug;12(8):621-638. doi: 10.1007/s13238-021-00835-w. Epub 2021 Apr 19. Protein Cell. 2021. PMID: 33871822 Free PMC article.
References
-
- Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat. Rev. Neurosci. 2014;15:394–409. - PubMed
-
- Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science (80-.) 2004;305:1010–1013. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01NS065053/NS/NINDS NIH HHS/United States
- R01NS087632/NS/NINDS NIH HHS/United States
- R01DA020812/DA/NIDA NIH HHS/United States
- R01 NS087632/NS/NINDS NIH HHS/United States
- R01 DA020812/DA/NIDA NIH HHS/United States
- R01 NS078007/NS/NINDS NIH HHS/United States
- R01 AG013730/AG/NIA NIH HHS/United States
- R01NS078007/NS/NINDS NIH HHS/United States
- R01 NS065053/NS/NINDS NIH HHS/United States
- F31 NS074517/NS/NINDS NIH HHS/United States
- R01AG013730/AG/NIA NIH HHS/United States
- F31NS074517/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases